Cogent Biosciences, Inc. (COGT) Key Metrics
COGT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $5.12B
- Enterprise value
- $4.97B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 861.2
- Price / book
- 11.7 10-yr median 2.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.31
COGT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCOGT valuation Price multiples at each fiscal year-end price.
Price / book+167.3%
9.0
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+19.5 pts
−4.7%
2025 · hover or tap a bar for each year
20162025
COGT returns How much profit the business earns on the capital it uses.
Return on equity+25.8 pts
−73.7%
2025 · hover or tap a bar for each year
20162025
Return on assets+27.8 pts
−52.0%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
COGT per-share figures Results divided by the shares outstanding at year-end.
Revenue per share
$0.00
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$2.04
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
−$1.65
2025 · hover or tap a bar for each year
20162025
Book value per share+70.4%
$3.95
2025 · hover or tap a bar for each year
20162025
Shares outstanding+45.7%
161.0M
2025 · hover or tap a bar for each year
20162025
COGT financial health Debt, liquidity and how easily interest is covered.
Debt / equity+483.7%
0.40
2025 · hover or tap a bar for each year
20162025
Net debt−$378.0M
−$647.6M
2025 · hover or tap a bar for each year
20162025
Current ratio+167.5%
14.23
2025 · hover or tap a bar for each year
20162025
Interest coverage
-108.9
2025 · hover or tap a bar for each year
20162025
Debt / assets+406.9%
0.27
2025 · hover or tap a bar for each year
20162025
COGT efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−90 days
850 days
2025 · hover or tap a bar for each year
20162025
COGT valuation history
Fiscal year-endToday10-year median
COGT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
COGT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
COGT price vs earnings per share
Share price at year-endEPS (right axis)
COGT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $5.72B | $861.6M | $468.4M | $679.0M | $332.3M | — | — | — | — | — |
| Enterprise value | $5.07B | $592.0M | $221.5M | $439.4M | $115.8M | — | — | — | — | — |
| Price / book | 9.0 | 3.4 | 1.8 | 2.7 | 1.6 | — | — | — | — | — |
| Earnings yield | −5.8% | −29.7% | −41.1% | −19.5% | −21.7% | — | — | — | — | — |
| Free cash flow yield | −4.7% | −24.2% | −33.4% | −18.5% | −18.2% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $35.52 | $7.80 | $5.88 | $11.56 | $8.58 | $11.23 | $2.88 | $17.60 | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$2.04 | −$2.32 | −$2.42 | −$2.26 | −$1.87 | — | — | — | — | — |
| Operating cash flow per share | −$1.64 | −$1.88 | −$1.93 | −$2.02 | −$1.52 | — | — | — | — | — |
| Free cash flow per share | −$1.65 | −$1.89 | −$1.96 | −$2.14 | −$1.56 | — | — | — | — | — |
| Cash per share | $5.60 | $2.60 | $3.34 | $4.41 | $5.67 | — | — | — | — | — |
| Book value per share | $3.95 | $2.32 | $3.24 | $4.35 | $5.53 | — | — | — | — | — |
| Tangible book value per share | $3.95 | $2.32 | $3.24 | $4.35 | $5.53 | — | — | — | — | — |
| Capex per share | $0.01 | $0.01 | $0.04 | $0.12 | $0.04 | — | — | — | — | — |
| Debt per share | $1.57 | $0.16 | $0.24 | $0.33 | $0.08 | — | — | — | — | — |
| Shares outstanding | 161.0M | 110.5M | 79.7M | 58.7M | 38.7M | — | — | — | — | — |
| Change in shares outstanding | +45.7% | +38.7% | +35.6% | +51.7% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −73.7% | −99.5% | −74.9% | −56.5% | −32.2% | −56.2% | −65.8% | −78.0% | −63.2% | −29.7% |
| Return on assets (ROA) | −52.0% | −79.8% | −62.6% | −49.8% | −29.9% | −49.8% | −44.7% | −51.1% | −40.9% | −21.3% |
| Return on tangible assets | −35.1% | −78.0% | −61.4% | −44.1% | −31.1% | −29.8% | −61.3% | −40.2% | −51.9% | −24.0% |
| Free cash flow margin | — | — | — | — | — | −455.5% | −184.7% | −339.4% | −319.9% | −345.4% |
| Financial health | ||||||||||
| Total debt | $253.2M | $17.5M | $18.9M | $19.6M | $3.2M | $5.2M | $6.0M | $3.8M | $2.8M | $1.2M |
| Cash & short-term investments | $900.8M | $287.1M | $265.7M | $259.3M | $219.7M | $242.2M | $37.4M | $78.6M | $41.0M | $68.5M |
| Net debt | −$647.6M | −$269.6M | −$246.9M | −$239.6M | −$216.5M | −$237.0M | −$31.4M | −$74.8M | −$38.2M | −$67.3M |
| Debt / equity | 0.40 | 0.07 | 0.07 | 0.08 | 0.01 | 0.02 | 0.19 | 0.06 | 0.10 | 0.02 |
| Debt / assets | 0.27 | 0.05 | 0.06 | 0.07 | 0.01 | 0.02 | 0.12 | 0.04 | 0.06 | 0.02 |
| Current ratio | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.79 | 7.98 |
| Quick ratio | 14.23 | 5.32 | 7.09 | 9.87 | 13.04 | 18.70 | 3.06 | 3.25 | 3.78 | 7.98 |
| Interest coverage | -108.9 | — | — | -37.1 | -24.1 | -570.8 | — | — | — | — |
| Working capital | $846.4M | $240.8M | $232.6M | $238.1M | $205.6M | $231.8M | $27.3M | $56.1M | $31.2M | $61.0M |
| Invested capital | −$11.2M | −$13.3M | $10.9M | $16.1M | −$2.3M | −$2.3M | $370,000 | −$14.6M | −$9.9M | −$14.9M |
| Tangible asset value | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M | $234.7M | $31.8M | $60.2M | $28.3M | $52.4M |
| Net current asset value | $609.1M | $224.9M | $215.1M | $219.9M | $204.7M | $228.7M | $22.9M | $55.3M | $21.6M | $46.6M |
| Graham net-net per share | $3.72 | $1.95 | $2.64 | $3.65 | $5.21 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | $0 | — | — | — | — |
| Capex / revenue | — | — | — | — | — | 4.1% | 0.1% | 5.6% | 10.9% | 52.0% |
| Capex / depreciation | 0.34 | 0.13 | 0.78 | 1.17 | 11.69 | 0.44 | 0.03 | 0.42 | 0.78 | 3.98 |
| Stock-based compensation / revenue | — | — | — | — | — | 76.4% | 14.4% | 31.7% | 16.0% | 16.0% |
| R&D / revenue | — | — | — | — | — | 923.0% | 194.3% | 393.3% | 356.8% | 346.1% |
| SG&A / revenue | — | — | — | — | — | 221.3% | 48.7% | 76.6% | 56.0% | 54.0% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | 46.4 | 29.8 | 46.8 | 38.4 | 35.1 |
| Days payables outstanding | 850.2 | 940.0 | 839.1 | 289.5 | 5,232.9 | 27.8 | 19,632.5 | — | — | — |
| Cash conversion cycle (days) | — | — | — | — | — | 18.6 | -19,602.7 | — | — | — |
| Receivables turnover | — | — | — | — | — | 7.87 | 12.27 | 7.79 | 9.51 | 10.40 |
| Payables turnover | 0.43 | 0.39 | 0.43 | 1.26 | 0.07 | 13.15 | 0.02 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | — | — | — | — | — | — | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.33 | 0.14 | 0.13 | 0.07 |
| Average receivables | — | — | — | — | — | $1.0M | $1.8M | $1.2M | $879,000 | $611,000 |
| Average payables | $10.8M | $11.3M | $8.2M | $4.7M | $2.1M | $2.0M | $2.4M | $1.4M | $1.4M | $1.4M |
| Average inventory | — | — | — | — | — | — | — | — | $75,000 | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from COGT's annual financial statements (latest annual report filed February 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
COGT valuation and financial ratios
Cogent Biosciences earned a return on equity of −73.7% in fiscal 2025. It ended the year with $253.2 million of debt and $900.8 million in cash and short-term investments, a net cash position of $647.6 million.
See the COGT income statement, the COGT chart for price history, or the COGT stock overview for the latest quote and news.
COGT key metrics FAQ
What is Cogent Biosciences's return on equity?
Cogent Biosciences's return on equity (ROE) was −73.7% in fiscal 2025: net income of -$328.9 million on average shareholders' equity of $446.3 million.
How much debt does Cogent Biosciences have?
Cogent Biosciences had total debt of $253.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.40 and more cash than debt.
What is Cogent Biosciences's free cash flow yield?
Cogent Biosciences generated -$266.0 million of free cash flow in fiscal 2025, a free cash flow yield of −4.7% on its market value at year-end ($5.7 billion).
What is Cogent Biosciences's current ratio?
Cogent Biosciences's current ratio was 14.23 at the end of fiscal 2025: current assets were 14.23 times current liabilities.